Comparative efficacy of Bruton tyrosine kinase inhibitors in high-risk relapsed/refractory CLL: a network meta-analysis.

Shadman M, Brown JR, Mohseninejad L, Yang K, Burnett H, Neupane B, Williams R, Lamanna N, O'Brien SM, Tedeschi A, Tam CS

Open source

DOI: 10.1182/bloodadvances.2024014523
Published: 2025 Jun 24
Container: Blood advances
Publisher: Not recorded
Open access: yes

Credibility signals

limited evidence Score 45/100 under policy 1.0.0. This is a metadata assessment, not a judgment of the paper's conclusions.

Show all credibility signals

cautionDOI registered: No matching Crossref record was present in this response. Source: Crossref; license: CC0 metadata
cautionDOI resolves: No matching Crossref record was present in this response. Source: Crossref; license: CC0 metadata
not scoredDirectory of Open Access Journals: No matching DOAJ record was present in this response. No allow-list match; this is not evidence of low credibility. Source: DOAJ; license: CC0
not scoredMEDLINE indexed: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredOpenAlex core source: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredKnown publisher allow-list: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredROR affiliation: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredRetraction Watch retraction: No retraction notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete. Source: Retraction Watch; license: CC BY 4.0
not scoredRetraction Watch expression of concern: No expression of concern notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete. Source: Retraction Watch; license: CC BY 4.0
not scoredRetraction Watch correction: No correction notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete. Source: Retraction Watch; license: CC BY 4.0
not scoredRetraction Watch reinstatement: No reinstatement notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete. Source: Retraction Watch; license: CC BY 4.0
supportingOpen access status: Normalized open-access status: open. Source: Normalized work metadata; license: Caller-provided; provenance license not supplied to scorer
not scoredPublication license: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredPublication version: A publication version was supplied but is not scored. Source: Normalized work metadata; license: Caller-provided; provenance license not supplied to scorer
cautionMetadata completeness: 5 of 6 scored descriptive metadata groups are present; missing fields increase uncertainty. Source: Normalized work metadata; license: Caller-provided; provenance license not supplied to scorer

Cite this work

BibTeX

@article{allodium:10.1182/bloodadvances.2024014523,
  title = {Comparative efficacy of Bruton tyrosine kinase inhibitors in high-risk relapsed/refractory CLL: a network meta-analysis.},
  author = {Shadman M and Brown JR and Mohseninejad L and Yang K and Burnett H and Neupane B and Williams R and Lamanna N and O'Brien SM and Tedeschi A and Tam CS},
  year = {2025},
  journal = {Blood advances},
  doi = {10.1182/bloodadvances.2024014523},
  url = {https://doi.org/10.1182/bloodadvances.2024014523}
}

RIS

TY  - JOUR
TI  - Comparative efficacy of Bruton tyrosine kinase inhibitors in high-risk relapsed/refractory CLL: a network meta-analysis.
AU  - Shadman M
AU  - Brown JR
AU  - Mohseninejad L
AU  - Yang K
AU  - Burnett H
AU  - Neupane B
AU  - Williams R
AU  - Lamanna N
AU  - O'Brien SM
AU  - Tedeschi A
AU  - Tam CS
PY  - 2025
JO  - Blood advances
DO  - 10.1182/bloodadvances.2024014523
UR  - https://doi.org/10.1182/bloodadvances.2024014523
ER  -

APA

M, S., JR, B., L, M., K, Y., H, B., B, N., R, W., N, L., SM, O., A, T., & CS, T. (2025). Comparative efficacy of Bruton tyrosine kinase inhibitors in high-risk relapsed/refractory CLL: a network meta-analysis.. Blood advances. https://doi.org/10.1182/bloodadvances.2024014523

Source records

pubmed · retrieved 2026-09-26T21:24:01.680Z